{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:49:08Z","timestamp":1788544148284,"version":"build-2803163510"},"reference-count":32,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chonnam National University Hospital Biomedical Research Institute (BCRE23215)","award":["BCRI121007"],"award-info":[{"award-number":["BCRI121007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy. A therapeutic regimen encompassing sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) has demonstrated strong efficacy across all genotypes of the hepatitis C virus (HCV) and has recently been incorporated into the Korean healthcare system. This study aimed to evaluate the real-world efficacy and safety of these antivirals in the South Korean population. Methods: This prospective, multicenter, observational study enrolled patients with chronic HCV treated with SOF\/VEL-based regimens at six hospitals between November 2022 and January 2024. DAA-na\u00efve patients received SOF\/VEL \u00b1 ribavirin for 12 weeks. Patients who had failed prior DAA therapy received SOF\/VEL\/VOX for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks post-treatment (SVR12). Results: Among 101 patients treated with SOF\/VEL, the mean age was 64.71 years, and 40.9% were male. Genotypes 1b and 2 were identified in 40.6% and 59.4% of patients, respectively. Two patients had a history of interferon-based treatment. The mean baseline HCV RNA level was 3,088,097 IU\/mL. Cirrhosis was observed in 26.7% of patients (21.8% compensated; 5.0% decompensated). Of the 101 patients, 12 were lost to follow-up. Among the 89 patients who completed follow-up, SVR12 was achieved in 100.0% (89\/89), including 5 patients with decompensated cirrhosis. In the SOF\/VEL\/VOX group, 17 patients were treated. The mean age was 61.84 years, 29.4% were male, and four had compensated cirrhosis. One patient was lost to follow-up. SVR12 was achieved in 100.0% (16\/16) of the patients who completed follow-up. No serious adverse events (\u2265grade 3) were reported in either group during the DAA treatment period. Conclusions: In this first prospective real-world study in South Korea, SOF\/VEL-based regimens demonstrated excellent efficacy and safety, achieving 100% SVR12 in the per-protocol population, including patients with cirrhosis and prior treatment failure.<\/jats:p>","DOI":"10.3390\/v17070949","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:19:27Z","timestamp":1751887167000},"page":"949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-2496","authenticated-orcid":false,"given":"Jae Hyun","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Jeonbuk National University Hospital and Medical School, Jeonju 54896, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon Gil","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Wonkwang University Hospital and Medical School, Iksan 54538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yeon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chosun University Hospital and Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9660-6303","authenticated-orcid":false,"given":"Jin Dong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Jeju Halla Hospital, Jeju 63127, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7001-7372","authenticated-orcid":false,"given":"Ga Ram","family":"You","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hwasun Chonnam National University Hospital and Medical School, Hwasun 58128, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Bum","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hwasun Chonnam National University Hospital and Medical School, Hwasun 58128, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Kyu","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chonnam National University Hospital and Medical School, Gwangju 61469, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, April 02). Hepatitis C Fact Sheet 2024, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606). J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3350\/cmh.2021.0155","article-title":"Sofosbuvir\/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and Panel, A.-I.H.G. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.17998\/jlc.2025.02.20","article-title":"Hepatocellular carcinoma in Korea: An analysis of the 2016-2018 Korean Nationwide Cancer Registry","volume":"25","author":"An","year":"2025","journal-title":"J. Liver Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.3346\/jkms.2021.36.e145","article-title":"Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: The Increasing Impact of Alcohol","volume":"36","author":"Yoon","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102671","DOI":"10.1016\/j.eclinm.2024.102671","article-title":"Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: A nationwide, multicentre, retrospective cohort study","volume":"73","author":"Sohn","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5009\/gnl19005","article-title":"Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study","volume":"14","author":"Nam","year":"2020","journal-title":"Gut Liver"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3904\/kjim.2022.252","article-title":"Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: A Phase 3b study","volume":"38","author":"Heo","year":"2023","journal-title":"Korean J. Intern. Med."},{"key":"ref_13","unstructured":"National Cancer Institute (2017). Common Terminology Criteria for Adverse Events (CTCAE) v5.0."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/jvh.12435","article-title":"A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus","volume":"22","author":"Lawitz","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/hepr.13810","article-title":"Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan","volume":"52","author":"Takehara","year":"2022","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan","volume":"11","author":"Cheng","year":"2022","journal-title":"Infect Dis. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100571","DOI":"10.1016\/j.jve.2024.100571","article-title":"Real-life study on the effectiveness and safety of sofosbuvir\/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients","volume":"10","author":"Wang","year":"2024","journal-title":"J. Virus Erad."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12072-023-10506-z","article-title":"Effectiveness and safety of 8-week glecaprevir\/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: Real-world experience from Taiwan nationwide HCV registry","volume":"17","author":"Chang","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.14874","article-title":"Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection","volume":"35","author":"Toyoda","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000501821","article-title":"Identifying Barriers to the Treatment of Chronic Hepatitis C Infection","volume":"38","author":"Patel","year":"2020","journal-title":"Dig. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s10620-018-5247-5","article-title":"Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C","volume":"63","author":"Marshall","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and Treatment Program to Eliminate Hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination","volume":"27","author":"Drenth","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5009\/gnl20321","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II\/III Trials","volume":"15","author":"Heo","year":"2021","journal-title":"Gut Liver"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jvh.13549","article-title":"Real world SOF\/VEL\/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy","volume":"28","author":"Smith","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.jhepr.2020.100138","article-title":"Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C","volume":"2","author":"Itakura","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"Nakamoto","year":"2014","journal-title":"World J. Gastroenterol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/949\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:04:35Z","timestamp":1760033075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070949"],"URL":"https:\/\/doi.org\/10.3390\/v17070949","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]}}}